Diagnosis and Treatment of Non-muscle Invasive Bladder Cancer
A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Oncology".
Deadline for manuscript submissions: closed (15 October 2021) | Viewed by 4800
Special Issue Editor
2. University of Duisburg – Essen, Department of Urology, Essen, Germany
Interests: bladder cancer: prevention; diagnostics; early detection; surgical techniques; urine-based tumor markers; risk assessment; intravesical treatment; immunotherapy; geriatric oncology
Special Issue Information
Dear Colleagues,
Bladder cancer is the second most frequent urothelial cancer that occurs most often in elderly patients. At first detection, about 75% of cases are non-muscle-invasive bladder cancers (NMIBC), with a generally high recurrence rate and a high risk of progression in some. This makes NMIBC not only a bothersome disease that requires long-term treatment and follow up for the patients but also a disease with a high socio-economic burden.
Since risk factors such as smoking and aromatic amines are well established, exposure reduction is mandatory. Further options are early detection and an optimal primary treatment with a combined treatment of transurethral resection and intravesical instillation including all kind of immunoncological approaches. In the future, histopathological subtype differentiation and testing for genetic tumour alterations will become more and more important in clinical routine.
Given the high importance of bladder cancer in the field of uro-oncology and research, the journal Medicina is launching this Special Issue.
We encourage you and your co-workers to submit your articles reporting on this topic. Reviews or original articles dealing with epidemiological aspects, the prevention and the early detection of bladder cancer are welcome. Further topics for this Special Issue should include optimized primary treatments, risk assessments and the optimal follow-up management of NMIBC. In addition, we warmly invite you to submit articles reporting on histopathological and molecular subtype differentiations of the bladder as well as the increasing relevance of genetic alterations in this disease.
Dr. Marcus Horstmann
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Bladder cancer
- Non-muscle-invasive bladder cancer
- Epidemiology
- Risk factors
- Transurehtral resection
- Early detection
- Intravesial treatment
- Subtype differentiation
- Genetic alterations
